novis pharma limited
novis pharma limited Company Information
Company Number
NI041771
Website
http://almacgroup.comRegistered Address
almac house, 20 seagoe industrial estate, craigavon, BT63 5QD
Industry
Dormant Company
Telephone
01737248794
Next Accounts Due
July 2025
Group Structure
View All
Shareholders
almac group (uk) ltd 100%
novis pharma limited Estimated Valuation
Pomanda estimates the enterprise value of NOVIS PHARMA LIMITED at £0 based on a Turnover of £10 and 0x industry multiple (adjusted for size and gross margin).
novis pharma limited Estimated Valuation
Pomanda estimates the enterprise value of NOVIS PHARMA LIMITED at £0 based on an EBITDA of £0 and a 0x industry multiple (adjusted for size and gross margin).
novis pharma limited Estimated Valuation
Pomanda estimates the enterprise value of NOVIS PHARMA LIMITED at £0 based on Net Assets of £2 and 0x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Novis Pharma Limited Overview
Novis Pharma Limited is a live company located in craigavon, BT63 5QD with a Companies House number of NI041771. It operates in the dormant company sector, SIC Code 99999. Founded in October 2001, it's largest shareholder is almac group (uk) ltd with a 100% stake. Novis Pharma Limited is a mature, micro sized company, Pomanda has estimated its turnover at £10.8 with low growth in recent years.
Upgrade for unlimited company reports & a free credit check
Novis Pharma Limited Health Check
Pomanda's financial health check has awarded Novis Pharma Limited a 0.5 rating. We use a traffic light system to show it exceeds the industry average on 0 measures and has 6 areas for improvement. Company Health Check FAQs
0 Strong
1 Regular
6 Weak
Size
annual sales of £10.8, make it smaller than the average company (£7.9m)
- Novis Pharma Limited
£7.9m - Industry AVG
Growth
3 year (CAGR) sales growth of 1%, show it is growing at a slower rate (6.7%)
- Novis Pharma Limited
6.7% - Industry AVG
Production
with a gross margin of 19.3%, this company has a higher cost of product (33.8%)
- Novis Pharma Limited
33.8% - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- Novis Pharma Limited
- - Industry AVG
Employees
with 1 employees, this is below the industry average (63)
- Novis Pharma Limited
63 - Industry AVG
Pay Structure
on an average salary of £40.8k, the company has an equivalent pay structure (£40.8k)
- Novis Pharma Limited
£40.8k - Industry AVG
Efficiency
resulting in sales per employee of £10.8, this is less efficient (£178.7k)
- Novis Pharma Limited
£178.7k - Industry AVG
Debtor Days
it gets paid by customers after 67 days, this is later than average (43 days)
- Novis Pharma Limited
43 days - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- Novis Pharma Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Novis Pharma Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Novis Pharma Limited
- - Industry AVG
Debt Level
There is insufficient data available for this Key Performance Indicator!
- - Novis Pharma Limited
- - Industry AVG
NOVIS PHARMA LIMITED financials
Novis Pharma Limited's latest turnover from October 2023 is estimated at £11 and the company has net assets of £2. According to their latest financial statements, we estimate that Novis Pharma Limited has 1 employee and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Oct 2023 | Oct 2022 | Oct 2021 | Oct 2020 | Oct 2019 | Oct 2018 | Oct 2017 | Oct 2016 | Oct 2015 | Oct 2014 | Oct 2013 | Oct 2012 | Oct 2011 | Oct 2010 | Oct 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | |||||||||||||||
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | |||||||||||||||
| Gross Profit | |||||||||||||||
| Admin Expenses | |||||||||||||||
| Operating Profit | |||||||||||||||
| Interest Payable | |||||||||||||||
| Interest Receivable | |||||||||||||||
| Pre-Tax Profit | |||||||||||||||
| Tax | |||||||||||||||
| Profit After Tax | |||||||||||||||
| Dividends Paid | |||||||||||||||
| Retained Profit | |||||||||||||||
| Employee Costs | |||||||||||||||
| Number Of Employees | |||||||||||||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Oct 2023 | Oct 2022 | Oct 2021 | Oct 2020 | Oct 2019 | Oct 2018 | Oct 2017 | Oct 2016 | Oct 2015 | Oct 2014 | Oct 2013 | Oct 2012 | Oct 2011 | Oct 2010 | Oct 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total assets | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| net assets | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total shareholders funds | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Oct 2023 | Oct 2022 | Oct 2021 | Oct 2020 | Oct 2019 | Oct 2018 | Oct 2017 | Oct 2016 | Oct 2015 | Oct 2014 | Oct 2013 | Oct 2012 | Oct 2011 | Oct 2010 | Oct 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | |||||||||||||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | ||||||||||
| Amortisation | 0 | 0 | 0 | 0 | 0 | ||||||||||
| Tax | |||||||||||||||
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creditors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | |||||||||||||||
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | |||||||||||||||
| interest | |||||||||||||||
| cash flow from financing | |||||||||||||||
| cash and cash equivalents | |||||||||||||||
| cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
novis pharma limited Credit Report and Business Information
Novis Pharma Limited Competitor Analysis
Perform a competitor analysis for novis pharma limited by selecting its closest rivals and benchmarking them against 12 key performance metrics.
novis pharma limited Ownership
NOVIS PHARMA LIMITED group structure
Novis Pharma Limited has no subsidiary companies.
Ultimate parent company
2 parents
NOVIS PHARMA LIMITED
NI041771
novis pharma limited directors
Novis Pharma Limited currently has 3 directors. The longest serving directors include Mr Alan Armstrong (Oct 2004) and Mr Stephen Campbell (May 2005).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Alan Armstrong | 65 years | Oct 2004 | - | Director | |
| Mr Stephen Campbell | 62 years | May 2005 | - | Director | |
| Mr Graeme McBurney | 54 years | Apr 2024 | - | Director |
P&L
October 2023turnover
10.8
+4%
operating profit
0
0%
gross margin
19.4%
-1.15%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
October 2023net assets
2
0%
total assets
2
0%
cash
0
0%
net assets
Total assets minus all liabilities
Similar Companies
novis pharma limited company details
company number
NI041771
Type
Private limited with Share Capital
industry
99999 - Dormant Company
incorporation date
October 2001
age
23
accounts
Dormant
ultimate parent company
previous names
l&b (no 8) limited (November 2002)
incorporated
UK
address
almac house, 20 seagoe industrial estate, craigavon, BT63 5QD
last accounts submitted
October 2023
novis pharma limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to novis pharma limited.
novis pharma limited Companies House Filings - See Documents
| date | description | view/download |
|---|
